SC 13G

Names of Reporting Persons

Frazier Life Sciences Public Fund, L.P.

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐ (b) ☒

SEC USE ONLY

Citizenship or Place of Organization

Delaware

SC 13G 1 d675523dsc13g.htm SC 13G SC 13G

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. ___)*

Trevi Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

89532M101

(CUSIP Number)

April 11, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 89532M101

(1)

Consists of (i) 684,000 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. and (ii) 1,926,458 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

(2)

Based on 30,805,804 shares of Common Stock outstanding on March 17, 2022 as set forth in the Issuer’s Form 10-K as filed with the SEC on March 17, 2022, (ii) 4,580,526 shares of Common Stock that were sold by the Issuer on April 11, 2021 as described in the Issuer’s Current Form 8-K filed with the SEC on April 7, 2022 and (iii) 1,926,458 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022.

CUSIP No. 89532M101

(1)

(2)

CUSIP No. 89532M101

(1)

(2)

CUSIP No. 89532M101

(1)

Consists of (i) 153,000 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (ii) 430,918 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

(2)

Based on 30,805,804 shares of Common Stock outstanding on March 17, 2022 as set forth in the Issuer’s Form 10-K as filed with the SEC on March 17, 2022, (ii) 4,580,526 shares of Common Stock that were sold by the Issuer on April 11, 2021 as described in the Issuer’s Current Form 8-K filed with the SEC on April 7, 2022 and (iii) 430,918 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022.

CUSIP No. 89532M101

(1)

(2)

Based on 30,805,804 shares of Common Stock outstanding on March 17, 2022 as set forth in the Issuer’s Form 10-K as filed with the SEC on March 17, 2022, (ii) 4,580,526 shares of Common Stock that were sold by the Issuer on April 11, 2021 as described in the Issuer’s Current Form 8-K filed with the SEC on April 7, 2022 and (iii) 430,918 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022.

CUSIP No. 89532M101

(1)

(2)

Based on 30,805,804 shares of Common Stock outstanding on March 17, 2022 as set forth in the Issuer’s Form 10-K as filed with the SEC on March 17, 2022, (ii) 4,580,526 shares of Common Stock that were sold by the Issuer on April 11, 2021 as described in the Issuer’s Current Form 8-K filed with the SEC on April 7, 2022 and (iii) 430,918 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022.

CUSIP No. 89532M101

(1)

Consists of (i) 163,000 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. and (ii) 459,083 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

(2)

Based on 30,805,804 shares of Common Stock outstanding on March 17, 2022 as set forth in the Issuer’s Form 10-K as filed with the SEC on March 17, 2022, (ii) 4,580,526 shares of Common Stock that were sold by the Issuer on April 11, 2021 as described in the Issuer’s Current Form 8-K filed with the SEC on April 7, 2022 and (iii) 459,083 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022.

CUSIP No. 89532M101

(1)

(2)

Based on 30,805,804 shares of Common Stock outstanding on March 17, 2022 as set forth in the Issuer’s Form 10-K as filed with the SEC on March 17, 2022, (ii) 4,580,526 shares of Common Stock that were sold by the Issuer on April 11, 2021 as described in the Issuer’s Current Form 8-K filed with the SEC on April 7, 2022 and (iii) 459,083 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022.

CUSIP No. 89532M101

(1)

(2)

Based on 30,805,804 shares of Common Stock outstanding on March 17, 2022 as set forth in the Issuer’s Form 10-K as filed with the SEC on March 17, 2022, (ii) 4,580,526 shares of Common Stock that were sold by the Issuer on April 11, 2021 as described in the Issuer’s Current Form 8-K filed with the SEC on April 7, 2022 and (iii) 459,083 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022.

CUSIP No. 89532M101

(1)

Consists of (i) 684,000 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 1,926,458 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022, (iii) 153,000 shares of Common Stock held directly by Frazier Life Sciences X, L.P., (iv) 430,918 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022, (v) 163,000 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. and (vi) 459,083 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

(2)

The actual percentage is 9.99%. Such percentage was calculated based on 30,805,804 shares of Common Stock outstanding on March 17, 2022 as set forth in the Issuer’s Form 10-K as filed with the SEC on March 17, 2022, (ii) 4,580,526 shares of Common Stock that were sold by the Issuer on April 11, 2021 as described in the Issuer’s Current Form 8-K filed with the SEC on April 7, 2022, (iii) 1,926,458 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022, (iv) 430,918 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022 and (v) 459,083 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022.

CUSIP No. 89532M101

(1)

(2)

CUSIP No. 89532M101

(1)

(2)

CUSIP No. 89532M101

(1)

(2)

CUSIP No. 89532M101

(1)

(2)

Based on 30,805,804 shares of Common Stock outstanding on March 17, 2022 as set forth in the Issuer’s Form 10-K as filed with the SEC on March 17, 2022, (ii) 4,580,526 shares of Common Stock that were sold by the Issuer on April 11, 2021 as described in the Issuer’s Current Form 8-K filed with the SEC on April 7, 2022 and (iii) 459,083 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to a warrant exercisable within 60 days of April 11, 2022.



Item 1(a).		Name of Issuer: Trevi Therapeutics, Inc.

Item 1(b).		Address of Issuer’s Principal Executive Offices: 195 Church Street, 14^th Floor, New Haven, Connecticut 06510

Item 2(a).		Name of Person Filing: The entities and persons filing this statement (collectively, the “Reporting Persons”) are: Frazier Life Sciences Public Fund, L.P. (“FLSPF”) FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences X, L.P. (“FLS X”) FHMLS X, L.P. FHMLS X, L.L.C. Frazier Life Sciences XI, L.P. (“FLS XI”) FHMLS XI, L.P. FHMLS XI, L.L.C. James N. Topper (“Topper”) Patrick J. Heron (“Heron”) Albert Cha (“Cha”) James Brush (“Brush”) Daniel Estes (“Estes” and together with Topper, Heron, Cha and Brush, the “Members”)

Item 2(b).		Address of Principal Business Office or, if none, Residence: The address and principal business office of the Reporting Persons is: c/o Frazier Healthcare Partners 601 Union Street, Suite 3200 Seattle, Washington 98101

Item 2(c).		Citizenship:


Entities:	FLSPF	-	Delaware, U.S.A.
	FHMLSP, L.P.	-	Delaware, U.S.A.
	FHMLSP, L.L.C.	-	Delaware, U.S.A.
	FLS X	-	Delaware, U.S.A.
	FHMLS X, L.P.	-	Delaware, U.S.A.
	FHMLS X, L.L.C.	-	Delaware, U.S.A.
	FLS XI	-	Delaware, U.S.A.
	FHMLS XI, L.P.	-	Delaware, U.S.A.
	FHMLS XI, L.L.C.	-	Delaware, U.S.A.

Individuals:	Topper	-	United States Citizen
	Heron	-	United States Citizen
	Cha	-	United States Citizen
	Brush	-	United States Citizen
	Estes	-	United States Citizen



Item 2(d).		Title of Class of Securities: Common Stock

Item 2(e).		CUSIP Number: 89532M101

Item 3.		If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:


(a)		☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)		☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)		☐ Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)		☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)		☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)		☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)		☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)		☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)		☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)		☐ A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

(k)		☐ Group, in accordance with §240.13d–1(b)(1)(ii)(K).

		If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

(a)

Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class: See Row 11 of cover page for each Reporting Person

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

Item 5.

Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Each member of the group is identified on Exhibit A to this Schedule 13G.

Item 9.

Notice of Dissolution of a Group

Not applicable.

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: April 18, 2022	FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
	By: FHMLSP, L.P., its General Partner
	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 18, 2022	FHMLSP, L.P.
	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 18, 2022	FHMLSP, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 18, 2022	FRAZIER LIFE SCIENCES X, L.P.
	By: FHMLS X, L.P., its General Partner
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 18, 2022	FHMLS X, L.P.
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 18, 2022	FHMLS X, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 18, 2022	FRAZIER LIFE SCIENCES XI, L.P.
	By: FHMLS XI, L.P., its General Partner
	By: FHMLS XI, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 18, 2022	FHMLS X,I L.P.
	By: FHMLS XI, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer


Date: April 18, 2022	FHMLS XI, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 18, 2022	By:	*
		James N. Topper

Date: April 18, 2022	By:	*
		Patrick J. Heron

Date: April 18, 2022	By:	**
		Albert Cha

Date: April 18, 2022	By:	**
		James Brush

Date: April 18, 2022	By:	**
		Daniel Estes

Date: April 18, 2022	By:	/s/ Steve R. Bailey
		Steve R. Bailey, as Attorney-in-Fact

*	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

**	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

***	This Schedule 13G was executed by Steve R. Bailey on behalf of the individual listed above pursuant to a Power of Attorney, a copy of which is included herewith as Exhibit B.

Exhibit Index


Exhibit A -		Agreement regarding filing of joint Schedule 13G.
Exhibit B -		Power of Attorney regarding Schedule 13 filings.

SEC Form SC 13G filed by Trevi Therapeutics Inc.